Controlling Cytokine Release Syndrome to Harness the Full Potential of CAR-Based Cellular Therapy
出版年份 2020 全文链接
标题
Controlling Cytokine Release Syndrome to Harness the Full Potential of CAR-Based Cellular Therapy
作者
关键词
-
出版物
Frontiers in Oncology
Volume 9, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2020-01-31
DOI
10.3389/fonc.2019.01529
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Early Administration of Tocilizumab (Toci) for the Prevention of Grade 4 Cytokine Release Syndrome (CRS) after CD19-directed CAR T-cell Therapy (CTL019)
- (2019) S. Kadauke et al. CYTOTHERAPY
- Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma
- (2019) Yaqing Cao et al. Frontiers in Oncology
- Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells
- (2018) Jae H Park et al. CLINICAL INFECTIOUS DISEASES
- Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
- (2018) David Porter et al. Journal of Hematology & Oncology
- Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
- (2018) Margherita Norelli et al. NATURE MEDICINE
- CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
- (2018) Theodoros Giavridis et al. NATURE MEDICINE
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome
- (2018) Robert Q. Le et al. ONCOLOGIST
- Cytokine release syndrome
- (2018) Alexander Shimabukuro-Vornhagen et al. Journal for ImmunoTherapy of Cancer
- Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy
- (2018) Jordan Gauthier et al. Current Research in Translational Medicine
- The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity
- (2018) Christopher W. Helsen et al. Nature Communications
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
- (2018) Wan-Hong Zhao et al. Journal of Hematology & Oncology
- Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes
- (2017) Carlos A. Ramos et al. JOURNAL OF CLINICAL INVESTIGATION
- Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib
- (2017) Cameron J. Turtle et al. JOURNAL OF CLINICAL ONCOLOGY
- Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity
- (2017) E Liu et al. LEUKEMIA
- CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma
- (2017) Andras Heczey et al. MOLECULAR THERAPY
- Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
- (2017) Justin Eyquem et al. NATURE
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
- (2017) Terry J Fry et al. NATURE MEDICINE
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- (2017) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
- (2017) Donald M. O’Rourke et al. Science Translational Medicine
- Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
- (2017) Juliane Gust et al. Cancer Discovery
- Rates and Trends of Pediatric Acute Lymphoblastic Leukemia — United States, 2001–2014
- (2017) David A. Siegel et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Toxicities of chimeric antigen receptor T cells: recognition and management
- (2016) Jennifer N. Brudno et al. BLOOD
- 2016 US lymphoid malignancy statistics by World Health Organization subtypes
- (2016) Lauren R. Teras et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors
- (2016) Kole T. Roybal et al. CELL
- CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies
- (2016) Annette Romanski et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
- (2016) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- Binding of the cytoplasmic domain of CD28 to the plasma membrane inhibits Lck recruitment and signaling
- (2016) Jessica Dobbins et al. Science Signaling
- Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
- (2016) D. T. Teachey et al. Cancer Discovery
- Binding of the cytoplasmic domain of CD28 to the plasma membrane inhibits Lck recruitment and signaling
- (2016) Jessica Dobbins et al. Science Signaling
- CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
- (2015) S. L. Maude et al. BLOOD
- T cell subsets and their signature cytokines in autoimmune and inflammatory diseases
- (2015) Itay Raphael et al. CYTOKINE
- Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome
- (2015) T. Oskarsson et al. HAEMATOLOGICA
- Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
- (2015) Nabil Ahmed et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
- (2015) Max S Topp et al. LANCET ONCOLOGY
- Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
- (2015) Alfred L. Garfall et al. NEW ENGLAND JOURNAL OF MEDICINE
- Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome
- (2015) T. Oskarsson et al. HAEMATOLOGICA
- The Fyn–ADAP Axis: Cytotoxicity Versus Cytokine Production in Killer Cells
- (2015) Zachary J. Gerbec et al. Frontiers in Immunology
- Antibody-modified T cells: CARs take the front seat for hematologic malignancies
- (2014) M. V. Maus et al. BLOOD
- Current concepts in the diagnosis and management of cytokine release syndrome
- (2014) D. W. Lee et al. BLOOD
- Engineered T cells for cancer therapy
- (2014) Carl H. June et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
- (2014) Shannon L. Maude et al. CANCER JOURNAL
- Distinct Regulation of Integrin-Dependent T Cell Conjugate Formation and NF- B Activation by the Adapter Protein ADAP
- (2014) B. J. Burbach et al. JOURNAL OF IMMUNOLOGY
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
- (2014) M. L. Davila et al. Science Translational Medicine
- Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor-Modified T Cells
- (2014) C. Berger et al. Cancer Immunology Research
- Murine natural killer immunoreceptors use distinct proximal signaling complexes to direct cell function
- (2013) R. M. May et al. BLOOD
- Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
- (2013) J. N. Kochenderfer et al. BLOOD
- Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells
- (2013) Xiao-Jun Xu et al. CANCER LETTERS
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
- Design and development of therapies using chimeric antigen receptor-expressing T cells
- (2013) Gianpietro Dotti et al. IMMUNOLOGICAL REVIEWS
- Use of Allogeneic Hematopoietic Stem-Cell Transplantation Based on Minimal Residual Disease Response Improves Outcomes for Children With Relapsed Acute Lymphoblastic Leukemia in the Intermediate-Risk Group
- (2013) Cornelia Eckert et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
- (2013) Richard A. Morgan et al. JOURNAL OF IMMUNOTHERAPY
- Signaling by Fyn-ADAP via the Carma1–Bcl-10–MAP3K7 signalosome exclusively regulates inflammatory cytokine production in NK cells
- (2013) Kamalakannan Rajasekaran et al. NATURE IMMUNOLOGY
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
- (2013) R. J. Brentjens et al. Science Translational Medicine
- Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma
- (2012) Christian Gisselbrecht et al. JOURNAL OF CLINICAL ONCOLOGY
- ADAP Regulates Cell Cycle Progression of T Cells via Control of Cyclin E and Cdk2 Expression through Two Distinct CARMA1-Dependent Signaling Pathways
- (2012) R. Srivastava et al. MOLECULAR AND CELLULAR BIOLOGY
- Chimeric Antigen Receptor Therapy for B-cell Malignancies
- (2012) David L Porter et al. Journal of Cancer
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
- (2011) J. N. Kochenderfer et al. BLOOD
- Transforming Growth Factor-β-activated Kinase 1 Regulates Natural Killer Cell-mediated Cytotoxicity and Cytokine Production
- (2011) Kamalakannan Rajasekaran et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients
- (2011) Barbara Savoldo et al. JOURNAL OF CLINICAL INVESTIGATION
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
- (2011) M. Kalos et al. Science Translational Medicine
- NF-κB Activation in T Cells Requires Discrete Control of IκB Kinase α/β (IKKα/β) Phosphorylation and IKKγ Ubiquitination by the ADAP Adapter Protein
- (2010) Rupa Srivastava et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Role of the LAT–PLC-γ1 Interaction in T Regulatory Cell Function
- (2010) Mariana I. Chuck et al. JOURNAL OF IMMUNOLOGY
- Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial
- (2010) Renier Brentjens et al. MOLECULAR THERAPY
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
- (2010) Richard A Morgan et al. MOLECULAR THERAPY
- Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor Eradication
- (2009) Xiao-Song Zhong et al. MOLECULAR THERAPY
- Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia
- (2008) S. Cooley et al. BLOOD
- Graft-versus-leukemia effects of transplantation and donor lymphocytes
- (2008) H.-J. Kolb BLOOD
- Multiple ITAM-coupled NK-cell receptors engage the Bcl10/Malt1 complex via Carma1 for NF- B and MAPK activation to selectively control cytokine production
- (2008) O. Gross et al. BLOOD
- Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study
- (2008) K Nguyen et al. LEUKEMIA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search